Skip to main content
Erschienen in: International Urology and Nephrology 1/2013

01.02.2013 | Urology - Original Paper

Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy

verfasst von: Jong Jin Oh, Sung Kyu Hong, Sangchul Lee, Seung June Sohn, Sang Eun Lee

Erschienen in: International Urology and Nephrology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate whether diabetes mellitus (DM) was associated with postoperative outcomes, including prostate-specific antigen doubling time, among men who underwent radical prostatectomy (RP) for clinically localized prostate cancer (PCa).

Methods

Data of 661 patients who underwent radical prostatectomy for node-negative prostate cancer and were followed up for ≥3 years postoperatively at our institution were analyzed. Associations between diabetes mellitus at surgery and outcomes following radical prostatectomy, such as biochemical recurrence-free survival and prostate-specific antigen doubling time, were examined. Aggressive recurrence was defined as biochemical recurrence with prostate-specific antigen doubling time <9 months.

Results

Of the 661 total subjects, DM (n = 67, 10.1 %) and non-DM group (n = 594, 89.9 %) showed no significant differences in various clinicopathologic parameters including age and PSA. DM group had lower postoperative biochemical recurrence-free survival than non-DM group, with observed difference approaching statistical significance (log-rank, p = 0.077). On multivariate analysis, DM at surgery was significantly associated with aggressive recurrence following RP (p = 0.048). Pathologic Gleason score (p = 0.008) and seminal vesicle invasion (p = 0.010) were also significantly associated with aggressive recurrence on multivariate analysis.

Conclusion

Our results show that pre-existing DM in men with PCa is associated with more aggressive recurrence, suggesting that DM may affect disease progression following RP. Further investigation would be needed to elucidate exact biologic interaction between DM and PCa and also assess causal relationships that potentially could be modified to improve long-term outcome in patients with the two diseases.
Literatur
1.
Zurück zum Zitat Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47(6):1071–10782PubMedCrossRef Bonovas S, Filioussi K, Tsantes A (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47(6):1071–10782PubMedCrossRef
2.
Zurück zum Zitat Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(11):2056–2062PubMedCrossRef Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15(11):2056–2062PubMedCrossRef
3.
Zurück zum Zitat Baradaran N, Ahmadi H, Salem S, Lotfi M, Jahani Y, Mehrsai AR, Pourmand G (2009) The protective effect of diabetes mellitus against prostate cancer: role of sex hormones. Prostate 69(16):1744–1750PubMedCrossRef Baradaran N, Ahmadi H, Salem S, Lotfi M, Jahani Y, Mehrsai AR, Pourmand G (2009) The protective effect of diabetes mellitus against prostate cancer: role of sex hormones. Prostate 69(16):1744–1750PubMedCrossRef
4.
Zurück zum Zitat Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124(6):1398–1403PubMedCrossRef Kasper JS, Liu Y, Giovannucci E (2009) Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 124(6):1398–1403PubMedCrossRef
5.
Zurück zum Zitat Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR (2005) History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control 16(7):789–797PubMedCrossRef Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR (2005) History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control 16(7):789–797PubMedCrossRef
6.
Zurück zum Zitat Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15(10):1977–1983PubMedCrossRef Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR (2006) Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 15(10):1977–1983PubMedCrossRef
7.
Zurück zum Zitat Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, Huang WY, Weiss JM, Danforth KN, Grubb RL 3rd, Andriole GL (2008) Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 19(10):1267–1276PubMedCrossRef Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, Huang WY, Weiss JM, Danforth KN, Grubb RL 3rd, Andriole GL (2008) Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 19(10):1267–1276PubMedCrossRef
8.
Zurück zum Zitat Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM (2010) Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76(5):1240–1244PubMedCrossRef Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM (2010) Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology 76(5):1240–1244PubMedCrossRef
9.
Zurück zum Zitat Jayachandran J, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ (2010) Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev 19(1):9–17PubMedCrossRef Jayachandran J, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ (2010) Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev 19(1):9–17PubMedCrossRef
10.
Zurück zum Zitat D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95(18):1376–1383PubMedCrossRef D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95(18):1376–1383PubMedCrossRef
11.
Zurück zum Zitat Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM (2006) Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92–02. Int J Radiat Oncol Biol Phys 66(4):1064–1071PubMedCrossRef Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM (2006) Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: an analysis of Radiation Therapy Oncology Group Protocol 92–02. Int J Radiat Oncol Biol Phys 66(4):1064–1071PubMedCrossRef
12.
Zurück zum Zitat Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4):433–439PubMedCrossRef Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4):433–439PubMedCrossRef
13.
Zurück zum Zitat Teeter AE, Banez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ (2008) What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol 180(5):1980–1984 discussion 1985PubMedCrossRef Teeter AE, Banez LL, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ (2008) What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol 180(5):1980–1984 discussion 1985PubMedCrossRef
14.
Zurück zum Zitat WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies Lancet 363(9403):157–163 WHO Expert Consultation (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies Lancet 363(9403):157–163
15.
Zurück zum Zitat Abdollah F, Briganti A, Suardi N, Gallina A, Capitanio U, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F (2011) Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? Prostate Cancer Prostatic Dis 14(1):74–78PubMedCrossRef Abdollah F, Briganti A, Suardi N, Gallina A, Capitanio U, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F (2011) Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? Prostate Cancer Prostatic Dis 14(1):74–78PubMedCrossRef
16.
Zurück zum Zitat Snyder CF, Stein KB, Barone BB, Peairs KS, Yeh HC, Derr RL, Wolff AC, Carducci MA, Brancati FL (2010) Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis 13(1):58–64PubMedCrossRef Snyder CF, Stein KB, Barone BB, Peairs KS, Yeh HC, Derr RL, Wolff AC, Carducci MA, Brancati FL (2010) Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis 13(1):58–64PubMedCrossRef
17.
Zurück zum Zitat Lee SE, Lee WK, Jeong MS, Abdullajanov M, Kim DS, Park HZ, Jeong SJ, Yoon CY, Byun SS, Choe G, Hong SK (2011) Is body mass index associated with pathological outcomes after radical prostatectomy in Korean men? BJU Int 107(8):1250–1255PubMedCrossRef Lee SE, Lee WK, Jeong MS, Abdullajanov M, Kim DS, Park HZ, Jeong SJ, Yoon CY, Byun SS, Choe G, Hong SK (2011) Is body mass index associated with pathological outcomes after radical prostatectomy in Korean men? BJU Int 107(8):1250–1255PubMedCrossRef
18.
Zurück zum Zitat Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E (2008) Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control 19(7):703–710PubMedCrossRef Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E (2008) Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control 19(7):703–710PubMedCrossRef
19.
Zurück zum Zitat Henderson KD, Goran MI, Kolonel LN, Henderson BE, Le Marchand L (2006) Ethnic disparity in the relationship between obesity and plasma insulin-like growth factors: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15(11):2298–2302PubMedCrossRef Henderson KD, Goran MI, Kolonel LN, Henderson BE, Le Marchand L (2006) Ethnic disparity in the relationship between obesity and plasma insulin-like growth factors: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15(11):2298–2302PubMedCrossRef
20.
Zurück zum Zitat Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, Fuchs CS (2003) Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21(3):433–440PubMedCrossRef Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, Fuchs CS (2003) Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21(3):433–440PubMedCrossRef
21.
Zurück zum Zitat Verlato G, Zoppini G, Bonora E, Muggeo M (2003) Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26(4):1047–1051PubMedCrossRef Verlato G, Zoppini G, Bonora E, Muggeo M (2003) Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care 26(4):1047–1051PubMedCrossRef
22.
Zurück zum Zitat Saydah SH, Loria CM, Eberhardt MS, Brancati FL (2003) Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157(12):1092–1100PubMedCrossRef Saydah SH, Loria CM, Eberhardt MS, Brancati FL (2003) Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 157(12):1092–1100PubMedCrossRef
23.
Zurück zum Zitat Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159(12):1160–1167PubMedCrossRef Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159(12):1160–1167PubMedCrossRef
24.
Zurück zum Zitat Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL, Wolff AC (2011) Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 29(1):40–46PubMedCrossRef Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL, Wolff AC (2011) Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 29(1):40–46PubMedCrossRef
25.
Zurück zum Zitat Hong SK, Oh JJ, Byun SS, Hwang SI, Lee HJ, Choe G, Lee SE (2012) Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥ = 12)-core prostate biopsy. Prostate 72(1):51–57PubMedCrossRef Hong SK, Oh JJ, Byun SS, Hwang SI, Lee HJ, Choe G, Lee SE (2012) Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi (≥ = 12)-core prostate biopsy. Prostate 72(1):51–57PubMedCrossRef
26.
Zurück zum Zitat Hong SK, Lee ST, Kim SS, Min KE, Byun SS, Cho SY, Choe G, Lee SE (2009) Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer. Prostate 69(8):820–826PubMedCrossRef Hong SK, Lee ST, Kim SS, Min KE, Byun SS, Cho SY, Choe G, Lee SE (2009) Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer. Prostate 69(8):820–826PubMedCrossRef
27.
Zurück zum Zitat Kim HS, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ (2010) Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate 70(14):1540–1546PubMedCrossRef Kim HS, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ (2010) Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate 70(14):1540–1546PubMedCrossRef
Metadaten
Titel
Diabetes mellitus is associated with short prostate-specific antigen doubling time after radical prostatectomy
verfasst von
Jong Jin Oh
Sung Kyu Hong
Sangchul Lee
Seung June Sohn
Sang Eun Lee
Publikationsdatum
01.02.2013
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 1/2013
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0306-x

Weitere Artikel der Ausgabe 1/2013

International Urology and Nephrology 1/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

06.05.2024 Insomnie Nachrichten

Chronische Insomnie als eigenständiges Krankheitsbild ernst nehmen und adäquat nach dem aktuellen Forschungsstand behandeln: Das forderte der Schlafmediziner Dr. Dieter Kunz von der Berliner Charité beim Praxis Update.

GLP-1-Rezeptoragonisten und SGLT-2-Hemmer: zusammen besser

06.05.2024 Typ-2-Diabetes Nachrichten

Immer häufiger wird ein Typ-2-Diabetes sowohl mit einem GLP-1-Rezeptor-Agonisten als auch mit einem SGLT-2-Inhibitor behandelt. Wie sich das verglichen mit den Einzeltherapien auf kardiovaskuläre und renale Komplikationen auswirkt, wurde anhand von Praxisdaten aus Großbritannien untersucht.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.